Costs and Outcomes of HIV/AIDS Treatment in Kenya
Like other countries throughout sub-Saharan Africa, Kenya is striving to offer effective HIV/AIDS care and treatment to all who need it. Coverage of the population in need in Kenya was reported to have reached 70% by 2009, representing some 337,000 patients. Until recently, however, there was no information available about the clinic-level costs of treating these patients. To help fill this gap, in 2007 the CGHD launched a small study of the costs and outcomes of adult antiretroviral therapy (ART) at three treatment sites in Kericho District in Southern Rift Valley Province. Researchers used the COAT Model (Costs and Outcomes of AIDS Treatment), which was developed by the CGHD in South Africa. In collaboration with the Kenya Medical Research Institute and the Walter Reed Projects of the U.S. government, the CGHD team collected medical record data on outcomes and resource utilization for patients at each site. They then estimated the average cost per patient initiated on ART and the average cost to achieve the successful outcome of a patient still in care and responding to treatment one year after initiation.
The study’s preliminary findings suggest that these Kenyan sites are achieving acceptable patient outcomes, consistent with those seen at public sector sites throughout the region, at extremely low cost. The average cost per patient per year on ART at these sites, which are all supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through the Walter Reed Projects, is around $250. This excludes inpatient care but includes ARVs, non-ARV drugs, laboratory tests, outpatient visits, clinic infrastructure, and other fixed costs. Final results for this three-site study are expected in early 2011.
This project is an activity under the CGHD’s ISHED: International Studies in Health and Economic Development.
|Principal Investigator||Sydney Rosen|
|Boston University Co-Investigators||Bruce Larson, Kelly McCoy|
|Dates of Research||2006–2010|